Undisclosed Logibody Program(s)

About Plectonic Biotech

Plectonic Biotech is a private, preclinical-stage biotech developing logic-gated immunotherapies via its proprietary Logibody platform. The technology uses DNA-based scaffolds to create conditionally active antibodies that only trigger an immune response upon recognizing specific tumor antigen patterns, aiming to enhance precision and reduce off-target effects common in current therapies. The company is advancing an undisclosed preclinical pipeline in oncology, positioning itself in the competitive field of next-generation targeted cancer treatments. As a platform-focused, pre-revenue company, its success hinges on validating its novel approach in clinical trials and securing strategic partnerships.

Therapeutic Areas